Home > Publications Database > Supplementation with short-chain fatty acids and a prebiotic improves clinical outcome in Parkinson's disease: a randomized double-blind prospective study. > print

001     283142
005     20260115103834.0
024 7 _ |a 10.1038/s41598-025-29692-x
|2 doi
024 7 _ |a pmid:41350593
|2 pmid
024 7 _ |a pmc:PMC12770440
|2 pmc
037 _ _ |a DZNE-2026-00038
041 _ _ |a English
082 _ _ |a 600
100 1 _ |a Hegelmaier, Tobias
|b 0
245 _ _ |a Supplementation with short-chain fatty acids and a prebiotic improves clinical outcome in Parkinson's disease: a randomized double-blind prospective study.
260 _ _ |a [London]
|c 2025
|b Springer Nature
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1768465519_11730
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Parkinson's disease is associated with a dysbiotic, proinflammatory gut microbiome, disruptions to intestinal barrier functions, and immunological imbalance. Microbiota-produced short-chain fatty acids, such as propionic and butyric acid promote gut barrier integrity and immune regulation, but their impact on Parkinson's disease pathology remains mostly unknown.In a randomized double-blind prospective study, 72 people with Parkinson's disease received propionic and butyric acid and/or the prebiotic fiber 2'-fucosyllactose supplementation over 6 months in combination with existing Parkinson's disease-specific therapy. Patients underwent complete neurological assessment and provided blood and stool samples before as well as 3 and 6 months after supplementation.We observed a robust improvement in motor symptoms, with all intervention groups achieving clinically meaningful reductions. These motor benefits were paralleled by clinically relevant reductions in levodopa medication. In contrast, effects on nonmotor symptoms were more heterogeneous. Notably, the interventions also modulated peripheral immune responses and enhanced mitochondrial respiration in immunocytes. Postintervention microbiota remodeled inflammatory and barrier-related gene sets in gut organ cultures and improved in vitro barrier functions. Treatment response was associated with microbiome composition, distinct patterns of colonic transcription and permeability ex vivo. Multiobjective analysis revealed immune parameters associated with an optimal response to supplementation.Short-chain fatty acids ameliorate clinical symptoms in Parkinson's disease patients and modulate intestinal and peripheral immunity.This clinical trial was retrospectively registered with the German Clinical Trials Register (DRKS), registration number DRKS00027061 on 11/19/2021.
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a Clinical improvement
|2 Other
650 _ 7 |a Gut microbiome
|2 Other
650 _ 7 |a Immunomodulation
|2 Other
650 _ 7 |a Neurodegeneration
|2 Other
650 _ 7 |a Neuroinflammation
|2 Other
650 _ 7 |a Parkinson’s disease
|2 Other
650 _ 7 |a Short chain fatty acids
|2 Other
650 _ 7 |a Prebiotics
|2 NLM Chemicals
650 _ 7 |a Fatty Acids, Volatile
|2 NLM Chemicals
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Parkinson Disease: microbiology
|2 MeSH
650 _ 2 |a Parkinson Disease: diet therapy
|2 MeSH
650 _ 2 |a Parkinson Disease: drug therapy
|2 MeSH
650 _ 2 |a Prebiotics: administration & dosage
|2 MeSH
650 _ 2 |a Male
|2 MeSH
650 _ 2 |a Double-Blind Method
|2 MeSH
650 _ 2 |a Female
|2 MeSH
650 _ 2 |a Fatty Acids, Volatile: administration & dosage
|2 MeSH
650 _ 2 |a Gastrointestinal Microbiome: drug effects
|2 MeSH
650 _ 2 |a Aged
|2 MeSH
650 _ 2 |a Middle Aged
|2 MeSH
650 _ 2 |a Dietary Supplements
|2 MeSH
650 _ 2 |a Prospective Studies
|2 MeSH
650 _ 2 |a Treatment Outcome
|2 MeSH
700 1 _ |a Duscha, Alexander
|b 1
700 1 _ |a Desel, Christiane
|b 2
700 1 _ |a Fuchs, Sabrina
|b 3
700 1 _ |a Shapira, Michal
|b 4
700 1 _ |a Amidror, Sivan
|b 5
700 1 _ |a Shan, Qihao
|b 6
700 1 _ |a Stangl, Gabriele I
|b 7
700 1 _ |a Hirche, Frank
|b 8
700 1 _ |a Kempa, Stefan
|b 9
700 1 _ |a Maifeld, András
|b 10
700 1 _ |a Würtele, Lisa-Marie
|b 11
700 1 _ |a Peplinski, Jana
|b 12
700 1 _ |a Jauk, Diana
|b 13
700 1 _ |a Naim, Gitali
|b 14
700 1 _ |a Shidlovsky, Nuphar
|b 15
700 1 _ |a Cohen, Adva
|b 16
700 1 _ |a Bennet, Yifat
|b 17
700 1 _ |a Paschold, Lisa
|b 18
700 1 _ |a Dumitru, Claudia A
|b 19
700 1 _ |a Obermüller-Jevic, Ute
|b 20
700 1 _ |a Hustvedt, Svein-Olaf
|b 21
700 1 _ |a Timmesfeld, Nina
|b 22
700 1 _ |a Gold, Ralf
|b 23
700 1 _ |a Zapf, Antonia
|b 24
700 1 _ |a Binder, Mascha
|b 25
700 1 _ |a Sandalcioglu, Ibrahim E
|b 26
700 1 _ |a Mostaghim, Sanaz
|b 27
700 1 _ |a Przuntek, Horst
|b 28
700 1 _ |a Segal, Eran
|b 29
700 1 _ |a Yissachar, Nissan
|b 30
700 1 _ |a Haghikia, Aiden
|0 P:(DE-2719)9001370
|b 31
|e Last author
|u dzne
773 _ _ |a 10.1038/s41598-025-29692-x
|g Vol. 16, no. 1, p. 315
|0 PERI:(DE-600)2615211-3
|n 1
|p 315
|t Scientific reports
|v 16
|y 2025
|x 2045-2322
856 4 _ |u https://pub.dzne.de/record/283142/files/DZNE-2026-00038%20SUP.zip
856 4 _ |y OpenAccess
|u https://pub.dzne.de/record/283142/files/DZNE-2026-00038.pdf
856 4 _ |y OpenAccess
|x pdfa
|u https://pub.dzne.de/record/283142/files/DZNE-2026-00038.pdf?subformat=pdfa
909 C O |o oai:pub.dzne.de:283142
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 31
|6 P:(DE-2719)9001370
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2024-12-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2024-12-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2024-12-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2024-12-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2024-12-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1040
|2 StatID
|b Zoological Record
|d 2024-12-18
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b SCI REP-UK : 2022
|d 2024-12-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2024-07-29T15:28:26Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2024-07-29T15:28:26Z
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2024-12-18
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2024-12-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2024-12-18
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
|d 2024-12-18
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2024-12-18
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2024-12-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1150
|2 StatID
|b Current Contents - Physical, Chemical and Earth Sciences
|d 2024-12-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2024-12-18
915 _ _ |a Creative Commons Attribution CC BY 4.0
|0 LIC:(DE-HGF)CCBY4
|2 HGFVOC
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2024-12-18
920 1 _ |0 I:(DE-2719)5000006
|k AG Düzel
|l Clinical Neurophysiology and Memory
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-2719)5000006
980 1 _ |a FullTexts

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21